| Development of effective ocular preparations of antifungal agents IP Kaur, C Rana, H Singh Journal of Ocular Pharmacology and Therapeutics 24 (5), 481-494, 2008 | 147 | 2008 |
| Ocular preservatives: associated risks and newer options IP Kaur, S Lal, C Rana, S Kakkar, H Singh Cutaneous and ocular toxicology 28 (3), 93-103, 2009 | 115 | 2009 |
| Nanostructured drug delivery for better management of tuberculosis IP Kaur, H Singh Journal of Controlled Release 184, 36-50, 2014 | 110 | 2014 |
| Development and evaluation of novel surfactant-based elastic vesicular system for ocular delivery of fluconazole IP Kaur, C Rana, M Singh, S Bhushan, H Singh, S Kakkar Journal of ocular pharmacology and therapeutics 28 (5), 484-496, 2012 | 108 | 2012 |
| Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH H Singh, R Bhandari, IP Kaur International journal of pharmaceutics 446 (1-2), 106-111, 2013 | 100 | 2013 |
| Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system IP Kaur, D Aggarwal, H Singh, S Kakkar Graefe's Archive for Clinical and Experimental Ophthalmology 248, 1467-1472, 2010 | 98 | 2010 |
| Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety H Singh, S Jindal, M Singh, G Sharma, IP Kaur International Journal of Pharmaceutics 485 (1-2), 138-151, 2015 | 59 | 2015 |
| Newer Therapeutic Vistas for Anti-Glaucoma Medicines SK Indu Pal Kaur, Harinder Singh Critical Reviews in Therapeutic Drug Carrier Systems 28, 165-202, 2011 | 19 | 2011 |
| Development and validation of an UPLC method for the quantification of ethambutol in rat plasma H Singh, G Sharma, IP Kaur RSC Advances 4 (81), 42831-42838, 2014 | 6 | 2014 |
